Know Cancer

or
forgot password

Evaluation of Response to Treatment Using 18F-FDG Positron Emission Tomography Imaging (PET) With Special Emphasize on the Prognostic Significance of Early On-therapy PET at First-line Treatment in Diffuse Large B-cell Lymphoma Stage IIB-IV


Phase 3
18 Years
N/A
Not Enrolling
Both
Diffuse Large-Cell Lymphoma

Thank you

Trial Information

Evaluation of Response to Treatment Using 18F-FDG Positron Emission Tomography Imaging (PET) With Special Emphasize on the Prognostic Significance of Early On-therapy PET at First-line Treatment in Diffuse Large B-cell Lymphoma Stage IIB-IV


Title: Evaluation of response to treatment using 18F-FDG positron emission tomography
imaging (PET) in diffuse large B-cell lymphoma stage IIB-IV with special emphasize on the
prognostic significance of early on-therapy PET at first-line treatment

Study design: Multicenter trial.

Planned sample size: 100 patients.

Number of centers: Denmark 2; Sweden 1; Norway 1; Finland 1.

Aim of the study: 1. To evaluate the prognostic significance of PET early after treatment
initiation. 2. To compare early PET with standard response criteria for NHL and the
International Prognostic Index (IPI) in the prediction of response and outcome.

Primary objective: The prognostic significance of FDG-PET after 1 cycle of chemotherapy.

End-points: Progression-free survival (PFS). Overall survival (OS). Response to treatment
(standardized response criteria) at mid-treatment and post-treatment.

Inclusion criteria:

Age ≥ 18 years. Newly diagnosed consecutive patients with diffuse large B-cell lymphoma
(DLBCL) according to the WHO classification.

Ann Arbor stage IIB-IV. Written informed consent.

Exclusion criteria: Previously treated with chemotherapy or irradiation. Previous malignant
diagnosis except basal cell carcinoma and cervical carcinoma in situ.

Pregnancy. Lactation. Diabetes mellitus. Extreme adipositas. Claustrophobia. Active
inflammatory disease or infection.

PET-CT evaluation: PET and CT at primary staging before initiation of therapy and PET after
one cycle of intravenous chemotherapy (day 10-20) are mandatory. The results of the PET
scans are blinded and will not be available for the local physicians. If the PET result is
opened, the patient will be excluded from the study.

Only post-treatment PET scans are allowed outside the protocol. The local physician may use
post-treatment PET in diagnostic or therapeutic considerations.

Only dedicated full-ring PET scanners are allowed in this study.

Treatment: Therapy with a CHOP-like backbone according to local standards of the individual
centers. Treatment according to other protocols allowed.


Inclusion Criteria:



- Age ≥ 18 years.

- Newly diagnosed consecutive patients with diffuse large B-cell lymphoma (DLBCL)
according to the WHO classification.

- Ann Arbor stage IIB-IV.

- Written informed consent.

Exclusion Criteria:

- Previously treated with chemotherapy or irradiation.

- Previous malignant diagnosis except basal cell carcinoma and cervical carcinoma in
situ.

- Pregnancy.

- Lactation.

- Diabetes mellitus.

- Extreme adipositas.

- Claustrophobia.

- Active inflammatory disease or infection.

Type of Study:

Observational

Study Design:

Observational Model: Case-Only, Time Perspective: Prospective

Principal Investigator

Lars M Pedersen, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Nordic Lymphoma Group (Large Cell Group)

Authority:

Denmark: Danish Medicines Agency

Study ID:

NLG PET Study

NCT ID:

NCT00286832

Start Date:

August 2005

Completion Date:

January 2011

Related Keywords:

  • Diffuse Large-Cell Lymphoma
  • Non-Hodgkin's lymphoma
  • Diffuse large B-cell lymphoma
  • PET
  • Prognosis
  • Lymphoma
  • Lymphoma, Large B-Cell, Diffuse
  • Lymphoma, Non-Hodgkin
  • Lymphoma, B-Cell

Name

Location